Business Description
Genelux Corp
NAICS : 541714
SIC : 2834
ISIN : US36870H1032
Total Employee Number:
26Description
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.72 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -13.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -129.1 | |||||
3-Year EPS without NRI Growth Rate | -55 | |||||
3-Year FCF Growth Rate | -66.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.92 | |||||
9-Day RSI | 40.06 | |||||
14-Day RSI | 41.48 | |||||
3-1 Month Momentum % | -9.22 | |||||
6-1 Month Momentum % | -1.85 | |||||
12-1 Month Momentum % | -25.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.39 | |||||
Quick Ratio | 2.39 | |||||
Cash Ratio | 2.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.3 | |||||
Shareholder Yield % | -16.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -455275 | |||||
Net Margin % | -444950 | |||||
EBITDA Margin % | -449250 | |||||
FCF Margin % | -358537.5 | |||||
OCF Margin % | -315962.5 | |||||
ROE % | -191.24 | |||||
ROA % | -132 | |||||
ROIC % | -622.79 | |||||
3-Year ROIIC % | 170.33 | |||||
ROC (Joel Greenblatt) % | -813.25 | |||||
ROCE % | -179.9 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.07 | |||||
Price-to-Tangible-Book | 7.01 | |||||
EV-to-EBIT | -2.69 | |||||
EV-to-Forward-EBIT | -2.71 | |||||
EV-to-EBITDA | -2.73 | |||||
EV-to-Revenue | 12249.25 | |||||
EV-to-Forward-Revenue | 8.3 | |||||
EV-to-FCF | -3.42 | |||||
| Price-to-Net-Current-Asset-Value | 12.63 | |||||
| Price-to-Net-Cash | 13.29 | |||||
Earnings Yield (Greenblatt) % | -37.17 | |||||
FCF Yield % | -25.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genelux Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.008 | ||
| EPS (TTM) ($) | -0.86 | ||
| Beta | 1.4922 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 119.26 | ||
| 14-Day RSI | 41.48 | ||
| 14-Day ATR ($) | 0.162544 | ||
| 20-Day SMA ($) | 2.656 | ||
| 12-1 Month Momentum % | -25.28 | ||
| 52-Week Range ($) | 2.29 - 8.535 | ||
| Shares Outstanding (Mil) | 45.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genelux Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genelux Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 57 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | 2.70 (+7.57%) | ||
| General meeting for 2026 | 2026-06-16 08:00 | 3.02 (+0.33%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.87 (+0.35%) | ||
| Annual report for 2025 | 2026-03-19 | 2.59 (-1.14%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 2.59 (-1.14%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 14:30 | 2.98 (+4.56%) | ||
| Oppenheimer Healthcare Life Sciences Conference | 2026-02-25 11:20 | 2.79 (+2.57%) | ||
| Virtual Fireside Chat Hosted by Titan Partners | 2026-01-19 09:00 | 2.74 (+5.38%) | ||
| Piper Sandler 37(th) Annual Healthcare Conference | 2025-12-03 12:00 | 4.73 (-3.67%) |
Show
Entries
Genelux Corp Frequently Asked Questions
What is Genelux Corp(GNLX)'s stock price today?
The current price of GNLX is $2.53. The 52 week high of GNLX is $8.54 and 52 week low is $2.29.
When is next earnings date of Genelux Corp(GNLX)?
The next earnings date of Genelux Corp(GNLX) is 2026-11-05 Est..
Does Genelux Corp(GNLX) pay dividends? If so, how much?
Genelux Corp(GNLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Genelux Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers